
tapedowngrad hold
morn announc acquir array per share
cash repres premium last
close price premium array day volum weight averag
price offer middl valuat rang
tabl look fair base upon past comp valuat model
view view posit biotech tape peer
downgrad hold adjust pt match offer
detail announc agreement discuss pfizer
confer call today etpleas call
outsid canada password analyst
base valuat analysi arri believ
share offer price fair array biopharma nr announc
acquir array per share cash
approxim enterpris valu deal repres
premium last close price premium tesaro day
volum weight averag price base valuat analysi
arri believ fair share price fall middl
valuat rang exhibit prior pt
 analysi includ averag bull case use peak sale
yield target premium multipl deal
biotech last year yield multipl
consensu sale base upon deal oncolog space yield
see exhibit term merger agreement
arri approv board director compani
transact expect complet
view news encourag potenti biotech space
view news encourag biotech spacepotenti
posit target therapi buy
also commerci compani mirati therapeut buy
compani strong chemistri incyt corpor buy
buy also similar target play colorect
buy hold
tr target
exhibit valuat model arri
exhibit recent biotech space
compani report strh research
potenti posit catalyst arri initi data binimetinib opdivo /- yervoy
mss phase updat keytruda advanc solid tumor
initi data binimetinib pembro /- chemo mss
valuat risk arri new pt base acquisit offer price beyond
clinic setback risk pt includ inabl differenti competit acquisit
close upsid risk includ better expect data mss colorect cancer
develop addit drug candid drive acquisit price prior close
page
catalyst next month highlight
page
assettimingcatalystcommentaryimpacttrialtargetpartnerencorafenib cetuximab erbitux binimetinibesmo-gi juli data braf-mut metastat colorect cancer posit result could support regulatori file acceler approvalmediumbeacon mek/braf/egfrbinimetinib opdivo /- data mss expect mpf squibbbinimetinib pembrolizumab /- data mss avelumab /- talazoparibiniti data pancreat updat solid tumor expect orr array biopharma inc
page
page
array biopharma commercial-stag biotech compani focus develop small molecul drug
predominantli target oncolog array deep domain expertis gener small molecul
drug partner multipl wholli own oncolog drug
array transit pipelin focus compani commerci entiti launch
braftovi encorafenib mektovi binimetinib expans addit indic
base pt acquisit price rate share hold
valuat risk
new pt base acquisit offer price beyond clinic setback risk
pt includ inabl differenti competit acquisit close upsid risk
includ better expect data mss colorect cancer develop addit drug
candid drive acquisit price prior close
compani mention note
peter lawson herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
suntrust robinson humphrey inc make market follow compani arry-u agio-u
exel-u incy-u mrtx-u
analyst compens base upon stock price perform qualiti analysi commun skill
overal revenu profit firm includ invest bank revenu
matter polici practic firm prohibit offer favor research specif
research rate specif target price consider induc receipt busi
compens addit associ person prepar research report prohibit own
secur subject compani
rate price target histori array biopharma inc arry-u
creat bluematrix
page
rate price target histori inc agio-u
rate price target histori inc exel-u
creat bluematrix
rate price target histori incyt corpor incy-u
creat bluematrix
creat bluematrix
rate price target histori inc mrtx-u
creat bluematrix
page
strh rate system equiti secur
dissemin research
suntrust robinson humphrey strh seek make reason effort provid research report
simultan elig client report avail publish restrict access area
websit elig client request password institut investor corpor
member press may also receiv research via third parti vendor includ thomson reuter
bloomberg factset capit iq addit distribut may done sale personnel via
email fax electron mean regular mail
access third parti vendor research websit http //suntrustlibrari bluematrix com/client/
pleas email research depart
contact strh sale repres
rate system effect oct
strh rate equiti secur
rate rel broader market gener next month unless
buy stock total return expect outperform relev benchmark
hold stock total return expect perform line relev benchmark
next month unless otherwis indic
sell stock total return expect under-perform relev benchmark
next month unless otherwis indic
rate nr strh invest rate opinion stock
coverag suspend cs indic strh rate and/or target price temporarili
suspend due applic regul and/or strh manag discret previous publish
rate target price reli upon
strh analyst price target stock cover unless otherwis indic price
target repres analyst expect stock trade next month unless
otherwis indic analyst believ insuffici valuat driver and/or invest
catalyst deriv posit neg invest view may elect approv strh
research manag assign target price likewis certain stock trade may
exhibit volatil wherebi assign price target would unhelp make invest decis
research manag approv analyst may refrain assign target sub-
legend rate price target histori chart
prior rate system oct
design base total return within period
buy total return low-beta secur
reduc total return neg low beta secur
neutral total return within bound
nr rate strh provid equiti research coverag
page
total return price appreci dividend price target within period unless
otherwis note beta defin secur averag beta less use bloomberg
suntrust robinson humphrey rate distribut
